In this issue:
Characteristics and prognosis of MM with light-chain deposition disease
Characteristics and outcomes of IgM myeloma
Daratumumab vs. historical data in heavily pretreated, refractory MM
Revised Myeloma Comorbidity
Index for predicting MM prognosis
SNPs associated with zoledronic acid-related osteonecrosis of the jaw in MM
Front-line carfilzomib-containing regimens for MM
Lenalidomide maintenance post-SCT in newly diagnosed MM
Isatuximab with lenalidomide/ dexamethasone for relapsed/ refractory MM
Immunoglobulin recovery 1- year post-SCT for predicting MM prognosis
Carfilzomib vs. bortezomib in relapsed/refractory MM by cytogenetic risk
Please login below to download this issue (PDF)